Cerity Partners
AVXL icon

Cerity Partners’s Anavex Life Sciences AVXL Stock Holding History

Cerity Partners’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$229K Buy
88,356
+74,186
+524% +$220K ﹤0.01% 2980
2026
Q1 		$43.5K Buy
+14,170
New +$61.4K ﹤0.01% 3121

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Cerity Partners's AVXL Position: Q2 2026 in Review

Cerity Partners increased its Anavex Life Sciences (AVXL) stake by 524% in Q2 2026, buying an estimated $220K and bringing the position to 88,356 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #2980.

Cerity Partners first reported a position in AVXL in Q1 2026 and has held it in 2 quarters since. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Cerity Partners held 88,356 shares of Anavex Life Sciences worth $229K as of Q2 2026.
  • Cerity Partners bought 74,186 Anavex Life Sciences shares in Q2 2026, an estimated $220K.
  • Anavex Life Sciences made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2980 holding.
  • Cerity Partners first reported a position in Anavex Life Sciences in Q1 2026 and has held it in 2 quarters since.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.